Highlights

  • Integrated Research Ltd (ASX:IRI) provides performance-management software through its Prognosis platform.
  • H1 FY26 pro forma Revenue was $34.4 million, while statutory revenue was $28.3 million.
  • Cash was $43.6 million at the end of H1 FY26, up 8% from June 2025.
  • At the time of writing this article on October 7, 2026, IRI was trading at AUD 0.28, up 1.82% during today’s trading session.

At the time of writing this article on October 7, 2026, Integrated Research Ltd (ASX:IRI) was trading at AUD 0.28, up 1.82% during today’s trading session. Integrated Research develops performance-management and analytics software used across payment systems, unified communications and information-technology infrastructure. The company’s 2026 reporting period has centred on softer revenue, continued product Investment and a cash position that provides capacity to fund its product-led strategy. Its FY26 full-year results were released in late August, following an interim period in which revenue declined and EBITDA moved into a loss.

Company Business

Integrated Research’s core platform is Prognosis, which provides monitoring, diagnostics and performance analytics for complex technology environments. Its Transact products monitor payment ecosystems, Collaborate supports voice, video and unified communications, and Infrastructure tools monitor enterprise systems including HPE NonStop environments. Customers include financial institutions, payment operators and telecommunications providers. Revenue is influenced by subscriptions, renewals, new Business and the timing of multi-year contracts.

Recent Development

Integrated Research released H1 FY26 results in February 2026 and followed with a full-year trading update in July before publishing FY26 results in August. Management has continued to focus on a product-led growth model, including investment in product capability, customer experience and simplification of go-to-market execution. The July update indicated that softer renewals and deferred new business affected the second half. The company also continued to emphasise the relevance of monitoring technology as enterprises adopt more complex digital communications and payments environments. In September, Integrated Research announced the date of its 2026 annual general meeting, placing governance and FY27 execution among the next scheduled Shareholder updates.

Financial Performance and Sector Context

For H1 FY26, Integrated Research reported pro forma revenue of $34.4 million and statutory revenue of $28.3 million. EBITDA was a loss of $3.1 million, compared with a profit in the prior corresponding period, while NPAT was a loss of $1.5 million. Cash at the end of the half was $43.6 million, up 8% from June 2025. The company’s July FY26 trading update indicated that full-year pro forma revenue was expected to be below the prior year because of softer renewals and weaker new business conversion. For software companies with a meaningful recurring-revenue component, renewal timing and contract duration can create variability between periods even when the underlying product remains embedded in customer operations.

Risks to Consider

Integrated Research faces renewal, customer-budget and product-execution risks. Large enterprise customers can delay purchasing decisions, affecting new business timing. The company must keep Prognosis relevant as payments, collaboration platforms and cloud architectures change. Competition can influence pricing and retention, while lower revenue could make continued product investment harder if cash generation weakens. Foreign-currency movements may also affect reported results.

What to Watch Next

The next areas to monitor include FY27 renewal performance, conversion of deferred new business, product-led initiatives and cash preservation. Investors may also watch whether management can improve EBITDA as revenue stabilises and whether software development produces higher customer retention or broader use of Prognosis. The Annual General Meeting and subsequent trading updates may provide additional detail on cost management and the pace of product investment. Because the company ended H1 FY26 with material cash, the rate at which that balance changes is also relevant when assessing the duration of the current investment phase.

Key Insights

Integrated Research remains positioned around mission-critical monitoring software, but FY26 highlighted the sensitivity of results to renewals and enterprise sales timing. The first-half figures showed lower revenue and a negative EBITDA result while cash remained material. The company’s strategy now depends on converting product investment into improved retention, new business and better operating leverage. Future assessment should focus on Recurring Revenue quality, renewal rates, new contract conversion, cost discipline and cash movement rather than short-term share-price changes.